FY2027 Earnings Estimate for Neogen Issued By Zacks Research

Neogen Corporation (NASDAQ:NEOG) – Stock analysts at Zacks Research increased their FY2027 earnings per share estimates for Neogen in a research note issued on Thursday, August 20th. Zacks Research analyst Team now expects that the company will post earnings of $0.25 per share for the year, up from their prior estimate of $0.21. The consensus estimate for Neogen’s current full-year earnings is $0.25 per share. Zacks Research also issued estimates for Neogen’s FY2029 earnings at $0.32 EPS.

A number of other research firms have also recently issued reports on NEOG. Weiss Ratings upgraded shares of Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Piper Sandler upgraded Neogen from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $13.00 to $14.00 in a research note on Wednesday. Finally, Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.00.

Neogen Stock Up 0.5%

NASDAQ:NEOG opened at $11.70 on Thursday. The company has a current ratio of 3.82, a quick ratio of 2.91 and a debt-to-equity ratio of 0.38. Neogen has a twelve month low of $4.90 and a twelve month high of $12.85. The company has a market cap of $2.55 billion, a PE ratio of -390.00, a P/E/G ratio of 4.59 and a beta of 1.77. The company’s 50 day moving average is $10.37 and its two-hundred day moving average is $9.85.

Neogen (NASDAQ:NEOG) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The firm had revenue of $225.30 million during the quarter, compared to analyst estimates of $212.35 million. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. Neogen’s revenue was down .1% on a year-over-year basis. During the same period last year, the firm posted ($2.82) EPS.

Institutional Trading of Neogen

Several large investors have recently made changes to their positions in NEOG. BlackRock Inc. purchased a new position in shares of Neogen during the second quarter worth $300,545,000. Dimensional Fund Advisors LP lifted its position in Neogen by 23.4% during the first quarter. Dimensional Fund Advisors LP now owns 9,132,021 shares of the company’s stock valued at $84,831,000 after purchasing an additional 1,733,767 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in Neogen by 249.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,181,768 shares of the company’s stock valued at $57,191,000 after purchasing an additional 5,838,570 shares during the last quarter. Mackenzie Financial Corp grew its position in Neogen by 1.0% during the 4th quarter. Mackenzie Financial Corp now owns 7,898,439 shares of the company’s stock worth $55,574,000 after purchasing an additional 79,010 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in Neogen during the 4th quarter worth about $47,983,000. 96.73% of the stock is owned by hedge funds and other institutional investors.

More Neogen News

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.